User profiles for "author:Sanjay de Mel"
Sanjay de MelDepartment of Haematology Oncology National University Cancer Institute Singapore Verified email at nuhs.edu.sg Cited by 1432 |
[HTML][HTML] Hematological abnormalities in COVID-19: a narrative review
ABSTRACT COVID-19 is caused by SARS-CoV-2. Although pulmonary manifestations have
been identified as the major symptoms, several hematological abnormalities have also been …
been identified as the major symptoms, several hematological abnormalities have also been …
[HTML][HTML] Molecular pathogenic pathways in extranodal NK/T cell lymphoma
S de Mel, SSS Hue, AD Jeyasekharan… - Journal of hematology & …, 2019 - Springer
Extranodal NK/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with a
dismal prognosis. Although l-asparaginase-based chemotherapy has resulted in improved …
dismal prognosis. Although l-asparaginase-based chemotherapy has resulted in improved …
[HTML][HTML] STAT3: a promising therapeutic target in multiple myeloma
Multiple myeloma (MM) is an incurable plasma cell malignancy for which novel treatment
options are required. Signal Transducer and Activator of Transcription 3 (STAT3) …
options are required. Signal Transducer and Activator of Transcription 3 (STAT3) …
[HTML][HTML] Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
CMM Wai, S Chen, T Phyu, S Fan, SM Leong… - …, 2022 - ncbi.nlm.nih.gov
Abstract Primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma (PTCL-EBV) is
a poorly understood disease which shows features resembling extranodal NK/T-cell …
a poorly understood disease which shows features resembling extranodal NK/T-cell …
Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis
PJ Teoh, O An, TH Chung, JY Chooi… - Blood, The Journal …, 2018 - ashpublications.org
DNA alterations have been extensively reported in multiple myeloma (MM); however, they
cannot yet fully explain all the biological and molecular abnormalities in MM, which remains …
cannot yet fully explain all the biological and molecular abnormalities in MM, which remains …
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin's
lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical …
lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical …
[HTML][HTML] Implications of heterogeneity in multiple myeloma
Multiple myeloma is the second most common hematologic malignancy in the world. Despite
improvement in outcome, the disease is still incurable for most patients. However, not all …
improvement in outcome, the disease is still incurable for most patients. However, not all …
[PDF][PDF] Favipiravir in COVID-19
The SARS-Cov-2 virus, emerged in December 2019 in Wuhan, China and has now spread
to all parts of the world. Many research groups are carrying out intense research on drugs …
to all parts of the world. Many research groups are carrying out intense research on drugs …
[HTML][HTML] Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection
Since emerging in China in December 2019, the infection caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) …
respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) …
A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma
XP Tian, SY Ma, KH Young, CK Ong… - Blood, The Journal …, 2021 - ashpublications.org
Current prognostic scoring systems based on clinicopathologic variables are inadequate in
predicting the survival and treatment response of extranodal natural killer/T-cell lymphoma …
predicting the survival and treatment response of extranodal natural killer/T-cell lymphoma …